Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

105

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
14/07/26	€0.1600	0.00%	85,500
13/07/26	€0.1600	0.00%	2,000
10/07/26	€0.1600	0.00%	0
09/07/26	€0.1600	0.00%	20,000
08/07/26	€0.1600	0.00%	38,000

Delayed Quote Börse Stuttgart

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.1803USD

Average target price

1.000USD

Spread / Average Target

+454.63%

Consensus

Annual profits - Rate of surprise

Company calendar

Market Closed - Börse Stuttgart Other stock markets 22:56:12 14/07/2026 +03			5-day change	1st Jan Change
0.1500 ^EUR	-6.25%		-6.25%	-27.18%

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	285M 250M 231M 213M 401M 27.42B 409M 2.75B 1.08B 13.4B 1.07B 1.05B 46.25B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	381M 334M 308M 285M 536M 36.66B 547M 3.68B 1.44B 17.92B 1.43B 1.4B 61.83B	EV / Sales 2026 *	-	EV / Sales 2027 *	10.5x
Free-Float	95.04%	Yield 2026 *	-	Yield 2027 *	-

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
05-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
04-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-15	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-14	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
31/10/25	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
27/10/25	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
24/10/25	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
27/08/25	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI
18/08/25	Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman	CI
15/08/25	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

07-08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
07-02	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
05-16	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ
04-30	Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform	PR
04-21	Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic	PR

Northwest Biotherapeutics, Inc. Stock Börse Stuttgart

Stocks

NBYB

US66737P6007

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc.

Chart: Northwest Biotherapeutics, Inc.

Latest news : Northwest Biotherapeutics, Inc.

Press Releases: Northwest Biotherapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Northwest Biotherapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

1 day	-6.25%
1 week	-6.25%
Current month	+3.45%
1 month	-16.67%
3 months	-7.41%
6 months	-28.57%
Current year	-27.18%

1 week	0.12	0.18
1 month	0.1	0.21
Current year	0.1	0.38
1 year	0.1	0.38
3 years	0.1	1.02
5 years	0.1	2.18
10 years	0.1	2.18

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	01/06/2007
Linda Powers CEO	Chief Executive Officer	71	08/06/2011
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	01/01/2000

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	01/01/1998
Linda Powers CHM	Chairman	71	17/05/2007
Navid Malik BRD	Director/Board Member	57	01/04/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NORTHWEST BIOTHERAPEUTICS, INC.	-6.25%	-6.25%	-	-	299M
WUXI APPTEC CO., LTD.	+6.05%	+7.79%	+62.23%	+88.46%	53.54B
ARGENX SE	+0.21%	-6.28%	+56.18%	+127.90%	54.18B
INSMED INCORPORATED	+0.89%	-2.42%	+8.07%	+434.51%	23.66B
BIONTECH SE	+0.37%	-4.13%	-18.56%	-16.48%	22.78B
WUXI BIOLOGICS (CAYMAN) INC.	+2.36%	+3.86%	+42.80%	-6.60%	19.54B
GENMAB A/S	-2.29%	-1.92%	+35.57%	-29.14%	17.82B
PHARMAESSENTIA CORPORATION	-4.00%	-10.96%	+181.91%	+328.17%	16.01B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.15%	-3.07%	+45.33%	+654.85%	15.37B
EXELIXIS, INC.	-0.48%	-2.30%	+22.36%	+187.62%	14.09B
Average	-0.43%	-1.47%	+48.43%	+196.59%	26.33B
Weighted average by Cap.	+1.18%	-0.46%	+48.69%	+164.08%

	2026 *	2027 *
Net sales	-	38.93M 34.09M 31.51M 29.07M 54.74M 3.75B 55.83M 376M 147M 1.83B 146M 143M 6.32B
Net income	-	-
Net Debt	96.08M 84.12M 77.76M 71.74M 135M 9.24B 138M 928M 364M 4.52B 361M 353M 15.59B	125M 109M 101M 93.29M 176M 12.02B 179M 1.21B 473M 5.87B 469M 459M 20.27B